FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2084260697> ?p ?o ?g. }

• W2084260697 endingPage "1210" @default.
• W2084260697 startingPage "1199" @default.
• W2084260697 abstract "The platelet glycoprotein (GP) IIb/IIIa integrin plays a key role in mediating platelet aggregation. Blockade of the platelet GP IIb/IIIa receptor prevents arterial thrombosis in animal models much better than does aspirin. Among the most specific inhibitors in this class of drugs is eptifibatide (Integrilin(TM), Millennium Pharmaceuticals, Inc.), a cyclic heptapeptide based on a peptide recognition sequence found in snake venom. Peptide inhibitors, such as eptifibatide, bind competitively to GP IIb/IIIa and have a short half-life, allowing the effect to be rapidly reversible and providing a favourable overall safety profile. Eptifibatide has been studied in a broad range of ischaemic coronary conditions including percutaneous coronary intervention (PCI), ST-segment and non-ST-segment acute myocardial infarction (MI) and unstable angina. In PCI and non-ST-segment MI, therapy with eptifibatide has been shown to reduce acute ischaemic complications without any increased risk of life-threatening adverse events. In the recently reported Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial, two 180 microg/kg boluses of eptifibatide, 10 min apart, followed by an 18 - 24 h infusion at 2 microg/kg/min given as adjunctive therapy in non-urgent PCI reduced the 30-day composite of death, MI and need for urgent target vessel revascularisation from 10.4 to 6.8% compared with placebo. These results were achieved under conditions of typical contemporary PCI, namely the implantation of second- and third-generation stents deployed at high balloon pressures along with modern adjunctive pharmacological treatment, particularly the universal use of thienopyridines and lower-dose heparin. Few significant pharmacological effects other than inhibition of platelet aggregation and the effect on bleeding time have been reported. Future research will focus on alternative clinical applications and combinations with other therapies to further improve cardiovascular outcomes." @default.
• W2084260697 created "2016-06-24" @default.
• W2084260697 creator A5036378793 @default.
• W2084260697 creator A5084989826 @default.
• W2084260697 date "2002-08-01" @default.
• W2084260697 modified "2023-10-17" @default.
• W2084260697 title "Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa" @default.
• W2084260697 cites W1481395580 @default.
• W2084260697 cites W1534784498 @default.
• W2084260697 cites W1563119717 @default.
• W2084260697 cites W1571377358 @default.
• W2084260697 cites W1588491159 @default.
• W2084260697 cites W1963594660 @default.
• W2084260697 cites W1981808231 @default.
• W2084260697 cites W1983198197 @default.
• W2084260697 cites W1987568997 @default.
• W2084260697 cites W1990988714 @default.
• W2084260697 cites W1994478916 @default.
• W2084260697 cites W1999922759 @default.
• W2084260697 cites W2012481680 @default.
• W2084260697 cites W2015606026 @default.
• W2084260697 cites W2026624464 @default.
• W2084260697 cites W2029231027 @default.
• W2084260697 cites W2033536477 @default.
• W2084260697 cites W2037465103 @default.
• W2084260697 cites W2044801740 @default.
• W2084260697 cites W2055126125 @default.
• W2084260697 cites W2085770049 @default.
• W2084260697 cites W2094687142 @default.
• W2084260697 cites W2105300288 @default.
• W2084260697 cites W2151363643 @default.
• W2084260697 cites W2230838014 @default.
• W2084260697 cites W2258528653 @default.
• W2084260697 cites W2274530116 @default.
• W2084260697 cites W2281862598 @default.
• W2084260697 cites W2327467387 @default.
• W2084260697 cites W3022148767 @default.
• W2084260697 cites W311320695 @default.
• W2084260697 cites W4245860073 @default.
• W2084260697 cites W4254730674 @default.
• W2084260697 cites W4256202725 @default.
• W2084260697 doi "https://doi.org/10.1517/14656566.3.8.1199" @default.
• W2084260697 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12150697" @default.
• W2084260697 hasPublicationYear "2002" @default.
• W2084260697 type Work @default.
• W2084260697 sameAs 2084260697 @default.
• W2084260697 citedByCount "41" @default.
• W2084260697 countsByYear W20842606972012 @default.
• W2084260697 countsByYear W20842606972013 @default.
• W2084260697 countsByYear W20842606972015 @default.
• W2084260697 countsByYear W20842606972016 @default.
• W2084260697 countsByYear W20842606972017 @default.
• W2084260697 countsByYear W20842606972018 @default.
• W2084260697 countsByYear W20842606972019 @default.
• W2084260697 countsByYear W20842606972020 @default.
• W2084260697 countsByYear W20842606972021 @default.
• W2084260697 countsByYear W20842606972022 @default.
• W2084260697 countsByYear W20842606972023 @default.
• W2084260697 crossrefType "journal-article" @default.
• W2084260697 hasAuthorship W2084260697A5036378793 @default.
• W2084260697 hasAuthorship W2084260697A5084989826 @default.
• W2084260697 hasConcept C126322002 @default.
• W2084260697 hasConcept C164705383 @default.
• W2084260697 hasConcept C2776335557 @default.
• W2084260697 hasConcept C2777628954 @default.
• W2084260697 hasConcept C2777698277 @default.
• W2084260697 hasConcept C2777785093 @default.
• W2084260697 hasConcept C2777849778 @default.
• W2084260697 hasConcept C2777871224 @default.
• W2084260697 hasConcept C2780400711 @default.
• W2084260697 hasConcept C2781056559 @default.
• W2084260697 hasConcept C3018697912 @default.
• W2084260697 hasConcept C45393284 @default.
• W2084260697 hasConcept C500558357 @default.
• W2084260697 hasConcept C71924100 @default.
• W2084260697 hasConcept C89560881 @default.
• W2084260697 hasConcept C98274493 @default.
• W2084260697 hasConceptScore W2084260697C126322002 @default.
• W2084260697 hasConceptScore W2084260697C164705383 @default.
• W2084260697 hasConceptScore W2084260697C2776335557 @default.
• W2084260697 hasConceptScore W2084260697C2777628954 @default.
• W2084260697 hasConceptScore W2084260697C2777698277 @default.
• W2084260697 hasConceptScore W2084260697C2777785093 @default.
• W2084260697 hasConceptScore W2084260697C2777849778 @default.
• W2084260697 hasConceptScore W2084260697C2777871224 @default.
• W2084260697 hasConceptScore W2084260697C2780400711 @default.
• W2084260697 hasConceptScore W2084260697C2781056559 @default.
• W2084260697 hasConceptScore W2084260697C3018697912 @default.
• W2084260697 hasConceptScore W2084260697C45393284 @default.
• W2084260697 hasConceptScore W2084260697C500558357 @default.
• W2084260697 hasConceptScore W2084260697C71924100 @default.
• W2084260697 hasConceptScore W2084260697C89560881 @default.
• W2084260697 hasConceptScore W2084260697C98274493 @default.
• W2084260697 hasIssue "8" @default.
• W2084260697 hasLocation W20842606971 @default.
• W2084260697 hasLocation W20842606972 @default.
• W2084260697 hasOpenAccess W2084260697 @default.
• W2084260697 hasPrimaryLocation W20842606971 @default.

• next